| 1 |
34964415 | Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. | 2022 May |
1 |
| 2 |
30194544 | Other Antidepressants. | 2019 |
4 |
| 3 |
30317998 | QSAR Analysis of Multimodal Antidepressants Vortioxetine Analogs Using Physicochemical Descriptors and MLR Modeling. | 2019 |
2 |
| 4 |
30457395 | Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. | 2019 Jan |
2 |
| 5 |
31835640 | Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats. | 2019 Dec 10 |
4 |
| 6 |
29174531 | Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. | 2018 Apr |
1 |
| 7 |
27781949 | Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. | 2017 |
2 |
| 8 |
26358483 | [Vortioxetine: a new antidepressant to treat depressive episodes]. | 2016 Feb |
1 |
| 9 |
26464458 | The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. | 2016 Jan |
1 |
| 10 |
26702943 | Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. | 2016 Apr |
1 |
| 11 |
26879252 | [Pharmacological properties of vortioxetine and its pre-clinical consequences]. | 2016 Feb |
1 |
| 12 |
25016186 | Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. | 2015 Jan |
1 |
| 13 |
25831967 | Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). | 2015 Apr |
1 |
| 14 |
25893002 | Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? | 2015 |
1 |
| 15 |
26192901 | [Antidepressants, stressors and the serotonin 1A receptor]. | 2015 Jun |
1 |
| 16 |
24165478 | Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? | 2014 Jan |
1 |
| 17 |
24311349 | Vortioxetine: first global approval. | 2014 Jan |
1 |
| 18 |
24676550 | Vortioxetine for the treatment of depression. | 2014 Jun |
1 |
| 19 |
25166025 | Vortioxetine for the treatment of major depressive disorder. | 2014 Nov |
3 |
| 20 |
25418918 | The efficacy of vortioxetine for the treatment of major depressive disorder. | 2014 Dec |
1 |
| 21 |
25717481 | [Cognitive dysfunctions in depression - underestimated symptom or new dimension?]. | 2014 Nov-Dec |
1 |
| 22 |
23428337 | 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. | 2013 Oct |
1 |